Company Overview of F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd. provides in-vitro diagnostics and drugs for cancer and transplantation. The company specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. Its products include cancer treatments, such as Avastin, Herceptin, and MabThera that are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. The company also researches, develops, and produces molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostic...
Founded in 1896
Key Executives for F. Hoffmann-La Roche Ltd
Chief Executive Officer of Roche Group
Compensation as of Fiscal Year 2015.
F. Hoffmann-La Roche Ltd Key Developments
F. Hoffmann-La Roche Ltd Announces Data from Phase III Idiopathic Pulmonary Fibrosis Analysis
Sep 29 15
F. Hoffmann-La Roche Ltd. has announced new clinical data from a pooled analysis of the ASCEND and CAPACITY Phase III studies for Esbriet in the treatment of idiopathic pulmonary fibrosis, or IPF. A pooled analysis from the ASCEND and CAPACITY Phase III studies showed a 38% reduction in risk of death (p=0.0515) in IPF patients who stayed on Esbriet treatment up to two years (120 weeks) compared with placebo. Previously reported data at one year showed the risk of mortality was reduced by 48% after treatment with Esbriet, a statistically significant result. The new data at 120 weeks show a strong trend in a reduced risk of death with long-term Esbriet treatment in IPF. Also presented at the ERS, an ad-hoc analysis of the pooled ASCEND and CAPACITY data showed patients who are hospitalised within the first six months of treatment saw their risk of disease progression (greater than or equal to 10% decline in lung function) or death reduced by more than two-thirds (relative difference = 72.2%) at one year by remaining on Esbriet treatment, compared with placebo. These clinical results show the benefits of continuing treatment. It is one of the first analyses on this topic and is of particular value for physicians and patients, as there is currently limited information to inform clinical decisions. Both analyses reinforced the well-established safety profile of Esbriet and were consistent with previous trial results. For more than four years, Esbriet has been available to physicians and IPF patients in Europe and was approved last year in the US.
F. Hoffmann-La Roche Ltd Announces Positive Results from Phase III Multiple Sclerosis Study
Sep 29 15
F. Hoffmann-La Roche Ltd. has announced positive results from a Phase III study that evaluated the investigational medicine, ocrelizumab, in people with primary progressive multiple sclerosis, or PPMS. The study (called ORATORIO) met its primary endpoint, showing treatment with ocrelizumab significantly reduced the progression of clinical disability sustained for at least 12 weeks compared with placebo, as measured by the Expanded Disability Status Scale (EDSS). Overall, the incidence of adverse events associated with ocrelizumab was similar to placebo; the most common adverse events were mild-to-moderate infusion-related reactions. The incidence of serious adverse events associated with ocrelizumab, including serious infections, was also similar to placebo. The positive study results observed with ocrelizumab in both people with PPMS (ORATORIO) as well as those with relapsing forms of MS (OPERA I and OPERA II) validate the hypothesis that B cells are central to the underlying biology of the disease. Roche plans to pursue marketing authorisation for ocrelizumab in relapsing MS and in PPMS. Data from the OPERA I and II studies and from the ORATORIO study will be submitted to global regulatory authorities in early 2016. ORATORIO is a Phase III, randomised, double-blind, global multi-centre study evaluating the efficacy and safety of ocrelizumab (600 mg administered by intravenous infusion every six months; given as two 300 mg infusions two weeks apart) compared with placebo in 732 people with PPMS. The primary endpoint of the ORATORIO study was time to onset of confirmed disability progression (CDP), defined as an increase in EDSS that is sustained for at least 12 weeks.
F. Hoffmann-La Roche Ltd Reports Earnings Results for the First Six Months Ended June 30, 2015
Jul 31 15
F. Hoffmann-La Roche Ltd. reported earnings results for the first six months ended June 30, 2015. For the six months period, the company reported net income attributable to shareholders of CHF 5.15 billion, or CHF 5.98 per diluted share, compared to CHF 5.53 billion, or CHF 6.41 per diluted share, for the same period ended June 30, 2014. Sales for the first six months ended June 30, 2015 were CHF 23.58 billion, compared to CHF 22.97 billion for the same period ended June 30, 2014. Operating profit for the first six months ended June 30, 2015 was CHF 7.71 billion, compared to CHF8.15 billion for the same period ended June 30, 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|